CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company specializing in therapeutics for nonalcoholic steatohepatitis (NASH), has announced the appointment of Ronald Filippo as the new Chief Information Officer. This latest appointment sees Filippo bringing more than 25 years of digital experience within the biopharmaceutical industry to Madrigal.
Filippo’s previous roles include Senior Vice President Digital at Moderna, where he led technology leadership and digital transformation across core operations during the commercialization of Moderna’s COVID-19 vaccine. His extensive experience also includes several positions of increasing responsibility at Teva Pharmaceuticals from 2008 to 2021, most recently as Head of Data and AI Transformation for North America.
Bill Sibold, Chief Executive Officer of Madrigal, expressed his confidence in the new appointment, stating, “Ron’s skillset and depth of digital experience will be a tremendous asset for Madrigal as we prepare for a first-to-market launch of resmetirom. His appointment reflects our commitment to leveraging AI and other digital technologies to enhance our business across the value chain, fulfill our ambitions for long-term growth, and innovate on behalf of patients with NASH.”
During his tenure at Moderna, Filippo achieved significant success through the use of AI, robotics, and equipment automation to optimize the manufacturing cycle and patient experience for a breakthrough personalized cancer vaccine. Prior to this, he developed a comprehensive data and AI strategy for Teva Pharmaceutical’s commercial operations.
In response to his appointment, Filippo stated, “I look forward to working with the Madrigal team to enhance the company’s information technology and AI capabilities during a pivotal period of growth and transformation. We have an exciting opportunity to build on Madrigal’s legacy of scientific innovation with new digital strategies that will improve care for patients with NASH.”
Filippo’s appointment comes at a crucial time as Madrigal prepares for the market launch of resmetirom, a novel therapeutic for NASH. His extensive experience and proven track record in digital transformation and AI strategy are expected to bring valuable insights and strategies to Madrigal’s operations and future growth.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.